Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSY244 in atrial fibrillation: randomized, placebo-controlled Phase 2 trial
2020-004327-17Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing HSY244 active treatment arm with Placebo comparator arm (2 arms). Primary endpoint: Conversion to sinus rhythm. Started Nov 2020; status: terminated.
02
Drugs
HSY244
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2020-004327-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004327-17.